Brought to you by 
Arachnova gets rights to Mitsubishi's MCI-225
02 Apr 2004
Executive Summary
Arachnova Therapeutics Ltd. (finds new uses for current drugs) has licensed rights to use, in the development of its own compounds AA10021, AA10025, and AA10026, data Mitsubishi Pharma obtained while developing its MCI-225.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arachnova gets rights to Mitsubishi's MCI-225
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice